Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

Haemophilia

Volumn 5, Issue 4, 1999, Pages 253-259

  Scharrer, I ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bleeding episodes; Factor VII deficiency; Haemophilia; Inhibitors; rFVIIa; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFANT; MALE; MULTICENTER STUDY; NAUSEA; NEWBORN; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOPHLEBITIS; VOMITING;

ADOLESCENT; ADULT; AGED; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VII DEFICIENCY; FACTOR VIIA; FACTOR VIII; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; INFANT; INTRACRANIAL HEMORRHAGES; INTRACRANIAL HYPERTENSION; ISOANTIBODIES; MALE; MIDDLE AGED; PREGNANCY; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0032884251     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00319.x     Document Type: Article

References (30)

1. Hedner U, Glazer S. Management of hemophilia patients with inhibitors. Coagulation Disorders 1. Hematol/Oncol Clinics North Am 1992; 6: 1035-46.
2. Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semin Thromb Hemost 1993; 19: 13-24.
3. Nilsson IM, Berntop E, Freiburghaus C. Treatment of patients with Factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56-9.
4. Brettler DB, Forsberg MS, Levine PH et al. on behalf of the Cooperating Investigators. The use of porcine factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 1381-5.
5. Brettler DB. Inhibitors in congenital haemophilia. In: Lee CA (ed.). Bailliere's Clinical Haematology: International Practice and Research, Vol. 9. Bailliere Tindall 1996: 320-9.
6. Hay CRM, Lozier JN, Lee CA et al. Porcine factor VIII in patients with congenital hemophilia and inhibitors: efficacy, patient selection and side effects. Semin Hematol 1994; 31: 20-5.
7. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors - benefits and limitations. Semin Hematol 1994; 31: 49-52.
8. Glazer S, Hedner U, Falch JF. Clinical update on the use of recombinant factor VIIa. Adv Exp Med Biol 1995; 386: 163-74.
9. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa: a review. Blood Coagul Fibrinol 1998; 9: 119-28.
10. Nicolaisen EM. Antigenicity of recombinant factor VIIa followed through nine years of clinical experience. Blood Coagul Fibrinol 1998; 9 (Suppl. 1): S119-S123.
11. Lund-Hansen T. NovoSeven - Virus safety. Haemostasis 1996; 26 (Suppl. 1): 96-7.
12. Makris M. Recombinant factor VIIa: The UK experience. International Society of Haematology, 1992. 24th Congress of the International Society of Haematology, South Bank Centre, London, UK, 23-8 August 1992.
13. Rice KM, Savidge GF. NovoSeven (recombinant factor VIIa) in central nervous system bleeds. Haemostasis 1996; 26 (Suppl. 1): 131-4.
14. Lusher J, Hedner U. and the NovoSeven Investigators. Treatment of internal hemorrhages with rFVIIa in patients with FVIII and FIX inhibitor antibodies. Haemophilia 1996; 2 (Suppl.): 31 (Abstract 117).
15. Mølskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26 (Suppl. 1): 135-8.
16. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 1): 118-23.
17. DiMichele D. The use of recombinant factor VIIa for central catheter insertion: an international experience. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, June 6-12, 1997. Thromb Haemost 1997; Suppl.: 167 (Abstract SC-679).
18. Hedner U. Factor VIIa as a universal haemostatic agent. Blood Coagul Fibrinol 1998; 9 (Suppl. 1): S147-S152.
19. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996; 26 (Suppl. 1): 102-8.
20. Roberts HR. Safety profile of recombinant factor VIIa: experience from clinical trials involving 503 patients. Haemophilia 1998; 4: 240 (Abstract 337).
21. Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in haemophiliacs with antibodies to factor VIII. a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-5.
22. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. N EnglJ Med 1981; 305: 717-58.
23. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
24. Kantrowitz JL, Lee ML, McClure DA, Kingdon HS, Thomas WR. Early experience with the use of antiinhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII. Clin Therapeutics 1987; 9 (4): 405-19.
25. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
26. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
27. Mariani G, Arcieri P, Testa MG, Hedner U. for the NovoSeven Study Group. Clinical use of recombinant, activated Factor VII in congenital factor VII deficiency. Haemophilia 1996; 2 (Suppl. 1): (Abstract 241).
28. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
29. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
30. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol 1998; 61 (Suppl. 63): 7-10.